Summary:
In 12,821 patients ≥50 years with T2D, elevated SBP (≥130 on meds or ≥140 untreated), and increased CV risk (CVD, CKD, or ≥2 risk factors), intensive BP treatment targeting SBP <120 mmHg for median 4.2 years reduced primary composite (stroke, MI, HF hospitalization, CV death) by 21% (HR 0.79, P<0.001) with achieved BP 121.6 vs 133.2 mmHg compared to standard treatment targeting <140 mmHg, with modestly increased symptomatic hypotension (0.1% vs <0.1%) and hyperkalemia (2.8% vs 2.0%) but similar serious AE rates.
| PICO | Description |
|---|---|
| Population | 12,821 patients ≥50y with T2D, elevated BP, and increased CV risk (CVD, CKD, or ≥2 risk factors). |
| Intervention | Intensive BP treatment targeting SBP <120 mmHg for median 4.2 years. |
| Comparison | Standard treatment targeting SBP <140 mmHg. |
| Outcome | Primary composite -21%. Stroke -21%. NNT ~72 over 4.2 years. |
Intensive BP control in type 2 diabetes (BPROAD)
RCT · type 2 diabetes · 4.2 years
Targeting SBP below 120 mmHg cut major cardiovascular events by 21% versus a below-140 mmHg target in high-risk patients with type 2 diabetes, with similar serious adverse-event rates.
Clinical Context
70-80% of diabetic patients have hypertension. ACCORD BP (2010) found no significant benefit from intensive control, but was underpowered.
Clinical Pearls
1. Intensive Control Definitively Reduces CV Events: 21% reduction settles debate. NNT 72 over 4.2 years.
2. Stroke Prevention Drives Benefit: Most robust finding consistent with hypertension’s stroke risk role.
3. Safety Concerns Are Modest: Similar serious AE rates despite more hypotension/hyperkalemia.
4. No Mortality Benefit Detected: Trends favored intensive treatment but not significant.
Practical Application
Target SBP <120 mmHg in high-risk diabetic patients. Use home BP monitoring. Check K+ after medication changes. Most need 2-3 agents.
Study Limitations
Chinese population. Open-label design. ~40% didn’t achieve <120 target. Long-term effects unknown.
Bottom Line
Intensive BP control (<120 mmHg) reduces major CV events by 21% in high-risk diabetic patients with acceptable safety.
Source: Bi Y, et al. “Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD).” NEJM, 2024. Read article